CCR5 antagonist 34   Click here for help

GtoPdb Ligand ID: 10106

PDB Ligand
Compound class: Synthetic organic
Comment: This CCR5 antagonist was designed to overcome some of the detrimental issues associated with the approved CCR5 antagonist maraviroc (an HIV entry inhibitor drug;) such as CYP450 inhibition, hERG inhibition and viral resistance [2]. It is one of the chemical structures claimed in patent WO2015101265A1 belonging to the Shanghai Institute of Materia Medica [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 91.29
Molecular weight 519.28
XLogP 6.21
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(C1CCC(CC1)(F)F)NC(c1ccsc1)CCN1C2CCC1CC(C2)n1c(C)nnc1C(C)C
Isomeric SMILES O=C(C1CCC(CC1)(F)F)N[C@H](c1ccsc1)CCN1[C@@H]2CC[C@H]1C[C@@H](C2)n1c(C)nnc1C(C)C
InChI InChI=1S/C27H39F2N5OS/c1-17(2)25-32-31-18(3)34(25)23-14-21-4-5-22(15-23)33(21)12-8-24(20-9-13-36-16-20)30-26(35)19-6-10-27(28,29)11-7-19/h9,13,16-17,19,21-24H,4-8,10-12,14-15H2,1-3H3,(H,30,35)/t21-,22+,23-,24-/m0/s1
InChI Key KESMRFWRGXZDEF-KIHHCIJBSA-N
Bioactivity Comments
Compound 34 does not inhibit CYP450 activity up to a concentration of 25 μM. This overcomes the potential drug-drug interaction of maraviroc which does have CYP450 inhibitory effects. It has no significant hERG liability (IC50 >40 μM).
Selectivity at GPCRs
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CCR5 Hs Antagonist Antagonist 8.5 pIC50 - 2
pIC50 8.5 (IC50 3x10-9 M) [2]
Description: In a whole cell intracellular calcium mobilisation assay using HEK293 cells expressing hCCR5.